F. Hoffmann-La Roche AG


About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the eleventh consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

Roche retains sole responsibility for content © 2020 F. Hoffmann-La Roche AG. All trademarks used or mentioned in this release are protected by law.

1 December 2018 - 30 November 2019

Region: Global
Subject/journal group: All

The table to the right includes counts of all research outputs for F. Hoffmann-La Roche AG published between 1 December 2018 - 30 November 2019 which are tracked by the Nature Index.

Hover over the donut graph to view the FC output for each subject. Below, the same research outputs are grouped by subject. Click on the subject to drill-down into a list of articles organized by journal, and then by title.

Note: Articles may be assigned to more than one subject area.

Count Share
139 48.63

Outputs by subject (Share)

Subject Count Share
Chemistry 23 12.08
7 4.72
2 1.40
2 0.36
De novo synthesis, structural assignment and biological evaluation of pseudopaline, a metallophore produced by Pseudomonas aeruginosa
Palladium-catalyzed enantioselective decarboxylative allylic alkylation of fully substituted N-acyl indole-derived enol carbonates
1 0.40
1 0.10
1 0.02
6 4.78
2 0.29
1 0
Life Sciences 119 36.65
Physical Sciences 5 0.93

Highlight of the month

Pliable protein helps cells die in multiple ways



A protein known to be involved in orderly cell death, when reconfigured, can also cause cells to die through excessive swelling leading to rupture, a mouse study has found.

Caspase-8 is a protein that classically triggers a controlled cell-death process involved in normal health and development, while suppressing an immune-mediated death mechanism implicated in responses to trauma or infection.

In the absence of both those functions, however, caspase-8 can rewire itself to galvanize yet another cell-destruction pathway, one characterized by extensive inflammation.

The finding — from a series of mouse experiments conducted at Genentech, a Roche subsidiary — exposes a previously unappreciated degree of flexibility between cell-death programs.

This molecular plasticity likely evolved to help cells fight off viral invaders. But the same adaptive process may be stymying efforts to treat certain chronic inflammatory diseases with drug therapies.

Supported content

  1. Nature 575, 679–682 (2019). doi: 10.1038/s41586-019-1752-8

View the article on the Nature Index

See more research highlights from F. Hoffmann-La Roche AG

More research highlights from F. Hoffmann-La Roche AG

1 December 2018 - 30 November 2019

International vs. domestic collaboration by Share

  • 7.1% Domestic
  • 92.9% International

Note: Hover over the graph to view the percentage of collaboration.

Note: Collaboration is determined by the fractional count (Share), which is listed in parentheses.

Affiliated joint institutions and consortia

Return to institution outputs